---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-22-001853"
form_type: "8-K"
ticker: "XBIO"
cik: "0001534525"
company_name: "Xenetic Biosciences, Inc."
filed_at: "2022-03-23T23:59:59+00:00"
generated_at: "2026-06-26T19:39:31.265811+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Xenetic reports FY2021 net loss of $5.6M; royalty revenue up 166% to $1.2M

## Summary
- Net loss for FY2021 was approx $5.6M; R&D expenses rose to $3.2M (vs $1.7M in 2020) on XCART investment.
- Cash at year-end $18.2M; working capital $17.3M, up from $11.4M in 2020.
- Royalty payments from PolyXen platform totaled $1.2M, up 166% YoY, from Takeda sublicensee product launches.
- XCART program advancing toward IND-enabling studies; U.S. patent for co-administration with personalized vaccine issued.

## SEC filing metadata
- accession: 0001683168-22-001853
- form_type: 8-K
- ticker: XBIO
- cik: 0001534525
- company_name: Xenetic Biosciences, Inc.
- filed_at: 2022-03-23T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1534525/000168316822001853/0001683168-22-001853-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1534525/000168316822001853/xenetic_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-22-001853
- JSON: https://secwatch.observer/filing/0001683168-22-001853.json
- Plain text: https://secwatch.observer/filing/0001683168-22-001853.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.